Quarterly report pursuant to Section 13 or 15(d)

Significant Strategic Collaborations (Details Narrative)

v3.23.3
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 17, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Royalty Income   $ 600,000 $ 400,000 $ 1,900,000 $ 1,200,000  
Research and development expenses   1,020,618 398,803 2,519,137 3,577,701  
Research and development expenses   1,480,562   1,480,562   $ 556,094
Initial payment for research $ 78,000          
Prepaid expenses and other   300,000   300,000    
Revenues   611,174 414,250 1,868,023 1,219,953  
Collaborative Agreements [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Revenues   0 $ 0 0 $ 0  
Catalent Pharma Solutions [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       2,400,000    
Research and development expenses   $ 900,000   900,000   $ 300,000
Scripps Research [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses 938,000          
Monthly payment $ 78,000          
Scripps Research [Member] | Scripps Agreement [Member]            
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]            
Research and development expenses       $ 500,000